1. Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS). (4th October 2017) Authors: Dorr, Mary Beth; Zeng, Zhen; Wilcox, Mark; Li, Junhua; Poxton, Ian; Zhao, Hailong; Li, Xiaoyun; Guris, Dalya; Shaw, Peter Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. (February 2020) Authors: Zeng, Zhen; Zhao, Hailong; Dorr, Mary Beth; Shen, Judong; Wilcox, Mark H.; Poxton, Ian R.; Guris, Dalya; Li, Junhua; Shaw, Peter M. Journal: Anaerobe Issue: Volume 61(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. (10th March 2018) Authors: Gerding, Dale N; Kelly, Ciaran P; Rahav, Galia; Lee, Christine; Dubberke, Erik R; Kumar, Princy N; Yacyshyn, Bruce; Kao, Dina; Eves, Karen; Ellison, Misoo C; Hanson, Mary E; Guris, Dalya; Dorr, Mary Beth Journal: Clinical infectious diseases Issue: Volume 67:Number 5(2018) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously. Issue 5 (30th November 2022) Authors: Ahonen, Anitta; Zhang, Ying; Marček, Tomáš; Lumley, Jessie; Johnson, David R.; Guris, Dalya; Wilck, Marissa B. Journal: Human vaccines & immunotherapeutics Issue: Volume 18:Issue 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. (19th October 2019) Authors: Kelly, Ciarán P; Poxton, Ian R; Shen, Judong; Wilcox, Mark H; Gerding, Dale N; Zhao, Xuemei; Laterza, Omar F; Railkar, Radha; Guris, Dalya; Dorr, Mary Beth Journal: Clinical infectious diseases Issue: Volume 71:Number 1(2020) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection. (16th May 2018) Authors: Birch, Thomas; Golan, Yoav; Rizzardini, Giuliano; Jensen, Erin; Gabryelski, Lori; Guris, Dalya; Dorr, Mary Beth Journal: Journal of antimicrobial chemotherapy Issue: Volume 73:Number 9(2018) Page Start: 2524 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence. (4th October 2017) Authors: Kelly, Ciaran P; Poxton, Ian R; Shen, Judong; Railkar, Radha; Guris, Dalya; Dorr, Mary Beth Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. (3rd August 2019) Authors: Wilcox, Mark H; Rahav, Galia; Dubberke, Erik R; Gabryelski, Lori; Davies, Kerrie; Berry, Claire; Eves, Karen; Ellison, Misoo C; Guris, Dalya; Dorr, Mary Beth Journal: Open forum infectious diseases Issue: Volume 6:Number 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. (19th January 2017) Authors: Boix, Vicente; Fedorak, Richard N.; Mullane, Kathleen M.; Pesant, Yves; Stoutenburgh, Uschi; Jin, Mandy; Adedoyin, Adedayo; Chesnel, Laurent; Guris, Dalya; Larson, Kajal B.; Murata, Yoshihiko Journal: Open forum infectious diseases Issue: Volume 4:Number 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗